A number of firms have modified their ratings and price targets on shares of CareDx (NASDAQ: CDNA) recently:
- 8/6/2026 – CareDx had its price target raised by BTIG Research from $45.00 to $60.00. They now have a “buy” rating on the stock.
- 8/3/2026 – CareDx was upgraded by Craig Hallum from “hold” to “buy”. They now have a $64.00 price target on the stock.
- 7/31/2026 – CareDx had its “neutral” rating reaffirmed by HC Wainwright. They now have a $46.00 price target on the stock.
- 7/30/2026 – CareDx was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
- 7/16/2026 – CareDx had its “hold” rating reaffirmed by Craig Hallum. They now have a $35.00 price target on the stock.
- 7/16/2026 – CareDx was upgraded by William Blair to “hold”.
- 7/16/2026 – CareDx had its price target raised by BTIG Research from $28.00 to $45.00. They now have a “buy” rating on the stock.
- 7/15/2026 – CareDx was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
- 6/26/2026 – CareDx was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
Insider Activity at CareDx
In other news, Director Christine Cournoyer sold 16,000 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $46.94, for a total transaction of $751,040.00. Following the sale, the director directly owned 42,943 shares in the company, valued at approximately $2,015,744.42. This represents a 27.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Hannah Valantine sold 12,103 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $23.11, for a total transaction of $279,700.33. Following the completion of the sale, the director owned 36,686 shares of the company’s stock, valued at $847,813.46. This trade represents a 24.81% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 114,936 shares of company stock worth $3,770,348. 2.40% of the stock is currently owned by corporate insiders.
The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.
Further Reading
- Five stocks we like better than CareDx
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for CareDx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc and related companies with MarketBeat.com's FREE daily email newsletter.
